NCT07152379Phase 2Not yet recruiting

Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Study sponsor: Cerus Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-09-30Estimated
Enrollment · participants25Estimated
Source updated2026-10-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 15 participants

Before: 10 participants (planned). After: 25 participants (planned).

Primary completion date changed

Before: 1 Oct 2027. After: 30 Sep 2030.

Check registry source